HOPE-基因组学干预提高癌症患者基因组学知识
帮助肿瘤患者探索基因组学 (HOPE-Genomics) 网络工具随机临床试验
This clinical trial studies the effectiveness of a web-based cancer education tool called Helping Oncology Patients Explore Genomics (HOPE-Genomics) in improving patient knowledge of personal genomic testing results and cancer and genomics in general. HOPE-Genomics is a web-based education tool that teaches cancer/leukemia patients, and patients who may be at high-risk for developing cancer, about genomic testing and provide patients with information about their own genomic test results. The HOPE-Genomics tool may improve patient's genomic knowledge and quality of patient-centered care. In addition, it may also improve education and care quality for future patients.
研究概览
地位
详细说明
PRIMARY OBJECTIVES:
I. Test the efficacy of the HOPE-Genomics intervention in improving patient knowledge of genomics.
II. Test the efficacy of the HOPE-Genomics intervention in improving patient receipt of guideline-concordant care.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I (USUAL CARE): Patients receive education pamphlet about whole-genome sequencing (WES) and have their genomics test results returned by their clinician in a typical manner.
ARM II (RETURN OF RESULTS ONLY): Patients receive their genomics test results both from their clinician and from the HOPE-Genomics tool. Patients then view HOPE-Genomics tool over 15-20 minutes after their results are available.
ARM III (RETURN OF RESULTS PLUS PRE-TEST EDUCATION): Patients view HOPE-Genomics tool (containing educational content) over 15-20 minutes before their sequencing results are available. Patients also receive their genomics test results both from their clinician and from the HOPE-Genomics tool.
After completion of study intervention, patients are followed up at 2 weeks, 3 and 9 months after receiving genomic test results.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
California
-
Duarte、California、美国、91010
- City of Hope Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Are enrolled in City of Hope (COH) Institutional Review Board (IRB) 07047
- Have a diagnosis of lung, breast, colorectal, pancreatic, ovarian or prostate cancer
- Having somatic, germline or paired somatic/germline sequencing
- Are fluent in English
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Are >= 18 years old
Exclusion Criteria:
- Are unable to provide informed consent
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Arm I (usual care)
Patients receive education pamphlet about WES and have their genomics test results returned by their clinician in a typical manner. |
Ancillary studies Receive usual care
其他名称:
|
|
实验性的:Arm II (genomics test results, HOPE-Genomics)
Patients receive their genomics test results both from their clinician and from the HOPE-Genomics tool. Patients then view HOPE-Genomics tool over 15-20 minutes after their results are available. |
Ancillary studies View HOPE-Genomics tool after genomic test results are available
其他名称:
View HOPE-Genomics before sequencing results are available
其他名称:
Receive genomics test results
其他名称:
|
|
实验性的:Arm III (HOPE-Genomics, genomics test results)
Patients view HOPE-Genomics tool (containing educational content) over 15-20 minutes before their sequencing results are available. Patients also receive their genomics test results both from their clinician and from the HOPE-Genomics tool. |
Ancillary studies View HOPE-Genomics tool after genomic test results are available
其他名称:
View HOPE-Genomics before sequencing results are available
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recall Rates of Personal Genomic Results
大体时间:Up to 3 months
|
Recall rate refers to the proportion of patients who accurately remembered whether they had undergone genetic testing, as reported in the 10-day follow-up survey. If a patient's response at the 10-day mark was unavailable, their answer from the 3-month survey was used as a substitute. This metric helps assess how well patients retained and understood information about their genetic testing experience shortly after receiving their results. |
Up to 3 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Operationalization of Contextual Guideline Concordant Care
大体时间:Up to 12-month period after results disclosure
|
In the primary analysis, we will assess the uptake of contextualized guideline-concordant care taking into account clinically relevant, patient specific circumstances. Will use clinical characteristics from the electronic health record (EHR) to assign each patient to clinical category for which there are discrete National Comprehensive Cancer Network (NCCN) recommendations. Using patient self-reported baseline/T1 and EHR data, following sequencing disclosure, we will create a summary genetically-guided care variable ranging from 0-100%. In the secondary analyses, will define guideline concordant as meeting >= 75% of recommended guidelines. |
Up to 12-month period after results disclosure
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Test-related Distress
大体时间:10 days, 3 months, 9 months
|
The psychosocial impact of genetic testing and patient uncertainty were assessed at 10 days, 3 months and 9 months using both the adapted PAGIS Certainty Scale and the FACToR. The FACToR was a 12-item measure that included four subscales: privacy concerns, uncertainty, test-related distress, and positive experiences. The overall FACToR score is computed by summing all items after reverse scoring the positivity subscale, resulting in a total range of 0 to 48. Higher total scores indicate greater psychosocial impact, which is considered a worse outcome. The PAGIS Certainty Subscale consists of 6 items scored on a 1-6 scale, with a total range of 6-36. Higher scores reflect greater certainty and better psychological adaptation to genetic information, which is considered a positive outcome. |
10 days, 3 months, 9 months
|
|
Genetically-guided Care
大体时间:Up to 9 months
|
In exploratory analyses related to Aim 2 (i.e. receipt of contextual guideline-concordant care), will also operationalize the secondary outcome in an additional way: Categories of genetically-guided care: Will evaluate patients' receipt of 1) treatment recommended by provider based on sequencing (any/none), 2) patients' sharing of sequencing results with family members (any/none), and 3) patients' consultation with genetic counseling/ recommended specialist (any/none). |
Up to 9 months
|
|
HOPE-Genomics Tool Usage
大体时间:Up to 9 months
|
Will analyze the web-log of user visits (e.g., number of viewing sessions, page views and use of interactive elements). |
Up to 9 months
|
|
Change in Genomic Knowledge Score
大体时间:baseline, pre-test (approximately 2-3 days after baseline), 10 days and 3 months
|
Genomic knowledge was assessed using a modified 35-item instrument comprising three subscales: cancer genomics knowledge, understanding of the use of genetic testing results in cancer care, and germline sequencing knowledge. Overall knowledge scores were calculated for patients who completed more than half of the items in the full measure. Each score was expressed as the percentage of correct responses out of the total number of questions answered in that category, with scores ranging from 0 to 100. The change in pre/post scores was calculated by taking the differences in knowledge scores from baseline to pre-test, 10-days and 3 months survey. |
baseline, pre-test (approximately 2-3 days after baseline), 10 days and 3 months
|
合作者和调查者
调查人员
- 首席研究员:Stacy W Gray、City of Hope Medical Center
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 生殖器疾病
- 内分泌系统疾病
- 生殖器肿瘤,男性
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 肿瘤
- 生殖器疾病,男性
- 前列腺疾病
- 男性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 肠道疾病
- 呼吸道疾病
- 消化道肿瘤
- 消化系统肿瘤
- 消化系统疾病
- 肠胃疾病
- 肠道肿瘤
- 直肠疾病
- 生殖器疾病,女性
- 肺部疾病
- 内分泌腺肿瘤
- 胰腺疾病
- 呼吸道肿瘤
- 胸部肿瘤
- 结肠疾病
- 卵巢疾病
- 附件疾病
- 生殖器肿瘤,女性
- 性腺疾病
- 皮肤病
- 乳腺疾病
- 皮肤和结缔组织疾病
- 前列腺肿瘤
- 肺肿瘤
- 结直肠肿瘤
- 卵巢肿瘤
- 乳腺肿瘤
- 胰腺肿瘤
- 卫生服务管理局
- 医疗保健质量,访问和评估
- 调查技术
- 医疗保健质量
- 质量指标,医疗保健
- 卫生服务
- 医疗机构的劳动力和服务
- 儿童健康服务
- 社区卫生服务
- 预防保健服务
- 社会经济因素
- 人口特征
- 遗传现象
- 指南作为主题
- 质量保证,医疗保健
- 遗传背景
- 方法
- 护理标准
- 早期干预,教育
- 教育地位
- 练习指南作为主题
- 遗传概况
其他研究编号
- 20430
- P30CA033572 (美国 NIH 拨款/合同)
- 20430 (其他标识符:City of Hope Medical Center)
- NCI-2021-03114 (注册表标识符:CTRP (Clinical Trial Reporting Program))
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.